Newsroom

Phase 2 clinical program in cholangiocarcinoma expected to start first half of 2022 

The Belgian start-up is developing an effective and reproducible phage therapy approach that offers a personalized solution to the major issue of AntiMicrobial Resistance (AMR)

New name reflects venture capital firm’s international expansion as group of entrepreneur-investors adding value in biotech
Name change follows launch of second fund in September 2021 with first close at €86M aimed at building tomorrow’s most promising biotech start-ups

MANTIS (Multiplex ANnotated Tissue Imaging System) was developed at Infinity (Inserm U1291, France) by Dr. Nicolas Gaudenzio and his team; Dr. Gaudenzio was recently appointed as Genoskin’s Chief Scientific Officer (CSO)

Genoskin licensed intellectual property from Inserm to develop MANTIS as a spatial biology platform dedicated to skin immunology and to characterizing drug effects on human skin

• Largest acquisition in history of Spanish biotechnology sector and largest operation to date for Caixa Capital Risc
• Holding 20% of the capital, Caixa Capital Risc is Sanifit’s biggest stakeholder and has supported company since 2006, participating in all financing rounds for a total investment of over €23M